Kiadis Pharma appoints Dr. Robert Friesen as CSO
Dr. Friesen will lead the Company's science, discovery and pre-clinical development activities and will be instrumental in building the Company’s scientific platform and identifying other programs for potential in-license. Dr. Friesen will report to Kiadis CEO Arthur Lahr and will be a member of the Company’s management team.
Dr. Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple Research and Development (R&D) organisations. Dr. Friesen joins Kiadis from Ablynx where he was CSO until its acquisition by Sanofi. At Ablynx, Dr. Friesen oversaw a team of more than 300 people who were responsible for more than 40 development-stage product candidates across a wide range of diseases.